Pterygium Research: Pterygium & VEGF: 48 articles as of 8/4/2014

Results: 48

1.
Concomitant examination of inflammation and angiogenesis in the pathogenesis of primary moderate pterygium in a well-designed case-control study.
Talghini S, Shenasi A.
Pak J Biol Sci. 2013 Oct 1;16(19):1046-50.
PMID:

 

24502169

 

[PubMed – indexed for MEDLINE]
Related citations
2.
S100A proteins as molecular targets in the ocular surface inflammatory diseases.
Tong L, Lan W, Lim RR, Chaurasia SS.
Ocul Surf. 2014 Jan;12(1):23-31. doi: 10.1016/j.jtos.2013.10.001. Epub 2013 Oct 22.
PMID:

 

24439044

 

[PubMed – in process]
Related citations
3.
Bevacizumab in the treatment of pterygium: a meta-analysis.
Hu Q, Qiao Y, Nie X, Cheng X, Ma Y.
Cornea. 2014 Feb;33(2):154-60. doi: 10.1097/ICO.0000000000000037.
PMID:

 

24326333

 

[PubMed – indexed for MEDLINE]
Related citations
4.
Expression of Vascular Endothelial Growth Factor (VEGF) in Macrophages, Fibroblasts, and Endothelial Cells in Pterygium Treated with 5-Fluorouracil.
Hoyama E, Viveiros MM, Shiratori C, Oliveira DE, Padovani CR, Selva D, Schellini SA.
Semin Ophthalmol. 2013 Oct 30. [Epub ahead of print]
PMID:

 

24171833

 

[PubMed – as supplied by publisher]
Related citations
5.
Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis ofpterygium.
Peng ML, Tsai YY, Tung JN, Chiang CC, Huang YC, Lee H, Cheng YW.
Br J Ophthalmol. 2014 Apr;98(4):556-61. doi: 10.1136/bjophthalmol-2013-303436. Epub 2013 Oct 11.
PMID:

 

24123908

 

[PubMed – indexed for MEDLINE]
Related citations
6.
Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection.
Lee S, Go J, Rhiu S, Stulting RD, Lee M, Jang S, Lee S, Kim HJ, Chung ES, Kim S, Seo KY.
Am J Ophthalmol. 2013 Sep;156(3):616-22.e3. doi: 10.1016/j.ajo.2013.01.035. Epub 2013 Apr 6.
PMID:

 

23570698

 

[PubMed – indexed for MEDLINE]
Related citations
7.
Overexpression of vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate.
Gumus K, Karakucuk S, Mirza GE, Akgun H, Arda H, Oner AO.
Br J Ophthalmol. 2014 Jun;98(6):796-800. doi: 10.1136/bjophthalmol-2012-301944. Epub 2013 Feb 1.
PMID:

 

23376569

 

[PubMed – indexed for MEDLINE]
Related citations
8.
Topical application of bevacizumab as an adjunct to recurrent pterygium surgery.
Ozgurhan EB, Agca A, Kara N, Yuksel K, Demircan A, Demirok A.
Cornea. 2013 Jun;32(6):835-8. doi: 10.1097/ICO.0b013e3182772d4e.
PMID:

 

23187164

 

[PubMed – indexed for MEDLINE]
Related citations
9.
Immunohistochemical profile of VEGF, TGF-β and PGE₂ in human pterygium and normal conjunctiva: experimental study and review of the literature.
Bianchi E, Scarinci F, Grande C, Plateroti R, Plateroti P, Plateroti AM, Fumagalli L, Capozzi P, Feher J, Artico M.
Int J Immunopathol Pharmacol. 2012 Jul-Sep;25(3):607-15. Review.
PMID:

 

23058011

 

[PubMed – indexed for MEDLINE]
Related citations
10.
Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium.
Ling S, Li Q, Lin H, Li W, Wang T, Ye H, Yang J, Jia X, Sun Y.
Eye (Lond). 2012 Nov;26(11):1451-8. doi: 10.1038/eye.2012.194. Epub 2012 Sep 14.
PMID:

 

22975656

 

[PubMed – indexed for MEDLINE] 

Free PMC Article

Related citations
11.
Expression of vascular endothelial growth factor C in human pterygium.
Fukuhara J, Kase S, Ohashi T, Ando R, Dong Z, Noda K, Ohguchi T, Kanda A, Ishida S.
Histochem Cell Biol. 2013 Feb;139(2):381-9. doi: 10.1007/s00418-012-1019-z. Epub 2012 Aug 23.
PMID:

 

22910845

 

[PubMed – in process]
Related citations
12.
Increasing lymphatic microvessel density in primary pterygia.
Ling S, Liang L, Lin H, Li W, Xu J.
Arch Ophthalmol. 2012 Jun;130(6):735-42. doi: 10.1001/archophthalmol.2012.293.
PMID:

 

22801834

 

[PubMed – indexed for MEDLINE]
Related citations
13.
The expression of vascular endothelial growth factor in mast cells promotes the neovascularisation of human pterygia.
Liang K, Jiang Z, Zhao B, Shen J, Huang D, Tao L.
Br J Ophthalmol. 2012 Sep;96(9):1246-51. doi: 10.1136/bjophthalmol-2012-301540. Epub 2012 Jul 11.
PMID:

 

22790437

 

[PubMed – indexed for MEDLINE]
Related citations
14.
Treatment of pterygium by ligation and bevacizumab injection.
Nakasato H, Uemoto R, Mizuki N.
Cornea. 2012 Nov;31(11):1339-41. doi: 10.1097/ICO.0b013e3182408bc7.
PMID:

 

22710493

 

[PubMed – indexed for MEDLINE]
Related citations
15.
Anterior segment uses of bevacizumab.
Bahar I, Yeung SN, Sella R, Slomovic A.
Curr Opin Ophthalmol. 2012 Jul;23(4):303-16. doi: 10.1097/ICU.0b013e3283548459. Review.
PMID:

 

22634640

 

[PubMed – indexed for MEDLINE]
Related citations
16.
Cyclooxygenase-2-expressing macrophages in human pterygium co-express vascular endothelial growth factor.
Park CY, Choi JS, Lee SJ, Hwang SW, Kim EJ, Chuck RS.
Mol Vis. 2011;17:3468-80. Epub 2011 Dec 29.
PMID:

 

22219642

 

[PubMed – indexed for MEDLINE] 

Free PMC Article

Related citations
17.
Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial.
Shenasi A, Mousavi F, Shoa-Ahari S, Rahimi-Ardabili B, Fouladi RF.
Cornea. 2011 Nov;30(11):1219-22. doi: 10.1097/ICO.0b013e31820ca63f.
PMID:

 

21955635

 

[PubMed – indexed for MEDLINE]
Related citations
18.
A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results.
Enkvetchakul O, Thanathanee O, Rangsin R, Lekhanont K, Suwan-Apichon O.
Cornea. 2011 Nov;30(11):1213-8. doi: 10.1097/ICO.0b013e31821c9b44.
PMID:

 

21915047

 

[PubMed – indexed for MEDLINE]
Related citations
19.
Angiogenesis in the pathogenesis of pterygium.
Livezeanu C, Crăiţoiu MM, Mănescu R, Mocanu C, Crăiţoiu S.
Rom J Morphol Embryol. 2011;52(3):837-44.
PMID:

 

21892527

 

[PubMed – indexed for MEDLINE] 

Free Article

Related citations
20.
Correlation of vascular endothelial growth factor and CD105-microvascular density in primarypterygium.
Zhang J, Zhang M, Li X, Zheng T, Mu G, Liu W, Xie H, Liu X.
J Huazhong Univ Sci Technolog Med Sci. 2011 Aug;31(4):560-4. doi: 10.1007/s11596-011-0490-4. Epub 2011 Aug 7.
PMID:

 

21823022

 

[PubMed – in process]
Related citations
21.
Tear film biomarkers as prognostic indicators for recurrent pterygium.
Zakaria N, De Groot V, Tassignon MJ.
Bull Soc Belge Ophtalmol. 2011;(317):53-4. No abstract available.
PMID:

 

21560859

 

[PubMed – indexed for MEDLINE]
Related citations
22.
Multiple subconjunctival bevacizumab for advanced primary pterygium.
Saxena S, Vishwkarma K, Khattri M, Kishore P.
Ann Ophthalmol (Skokie). 2010;42 Spec No:28-30.
PMID:

 

21138148

 

[PubMed – indexed for MEDLINE]
Related citations
23.
The effect of subconjunctival ranibizumab on primary pterygium: a pilot study.
Mandalos A, Tsakpinis D, Karayannopoulou G, Tsinopoulos I, Karkavelas G, Chalvatzis N, Dimitrakos S.
Cornea. 2010 Dec;29(12):1373-9. doi: 10.1097/ICO.0b013e3181d927b9.
PMID:

 

20856107

 

[PubMed – indexed for MEDLINE]
Related citations
24.
Antivascular endothelial growth factors in anterior segment diseases.
Scholl S, Kirchhof J, Augustin AJ.
Dev Ophthalmol. 2010;46:133-9. doi: 10.1159/000320016. Epub 2010 Aug 10.
PMID:

 

20703039

 

[PubMed – indexed for MEDLINE]
Related citations
25.
Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoingpterygium surgery.
Galor A, Yoo SH, Piccoli FV, Schmitt AJ, Chang V, Perez VL.
Am J Ophthalmol. 2010 Jun;149(6):926-931.e2. doi: 10.1016/j.ajo.2010.01.015. Epub 2010 Apr 24.
PMID:

 

20417925

 

[PubMed – indexed for MEDLINE]
Related citations
26.
Growth factor expression in ophthalmic pterygia and normal conjunctiva.
Detorakis ET, Zaravinos A, Spandidos DA.
Int J Mol Med. 2010 Apr;25(4):513-6.
PMID:

 

20198298

 

[PubMed – indexed for MEDLINE]
Related citations
27.
Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.
Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M.
Curr Eye Res. 2010 Jan;35(1):17-22. doi: 10.3109/02713680903395273.
PMID:

 

20021250

 

[PubMed – indexed for MEDLINE]
Related citations
28.
The change of cytokines in tear and blood after different pterygium operation.
Lee JK, Song YS, Shin JS, Kwon YS, Shin MS, Kim JC.
Cytokine. 2010 Feb;49(2):148-54. doi: 10.1016/j.cyto.2009.11.008. Epub 2009 Dec 8.
PMID:

 

20004113

 

[PubMed – indexed for MEDLINE]
Related citations
29.
Preliminary results of subconjunctival bevacizumab in primary pterygium excision.
Razeghinejad MR, Hosseini H, Ahmadi F, Rahat F, Eghbal H.
Ophthalmic Res. 2010;43(3):134-8. doi: 10.1159/000252980. Epub 2009 Oct 29.
PMID:

 

19887878

 

[PubMed – indexed for MEDLINE]
Related citations
30.
Immunohistochemical analysis of vascular endothelial growth factor (VEGF) and p53 expression inpterygium from Tunisian patients.
Khalfaoui T, Mkannez G, Colin D, Imen A, Zbiba W, Errais K, Anane R, Beltaief O, Zhioua R, Ben Hamida J, Lizard G, Ouertani-Meddeb A.
Pathol Biol (Paris). 2011 Jun;59(3):137-41. doi: 10.1016/j.patbio.2009.04.006. Epub 2009 May 28.
PMID:

 

19481369

 

[PubMed – indexed for MEDLINE]
Related citations
31.
Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment.
Mauro J, Foster CS.
Semin Ophthalmol. 2009 May-Jun;24(3):130-4. doi: 10.1080/08820530902801106. Review.
PMID:

 

19437347

 

[PubMed – indexed for MEDLINE]
Related citations
32.
[Antiangiogenic therapy for pterygium recurrence].
Leippi S, Grehn F, Geerling G.
Ophthalmologe. 2009 May;106(5):413-9. doi: 10.1007/s00347-009-1936-y. German.
PMID:

 

19418056

 

[PubMed – indexed for MEDLINE]
Related citations
33.
Effect of subconjunctival bevacizumab on primary pterygium.
Teng CC, Patel NN, Jacobson L.
Cornea. 2009 May;28(4):468-70. doi: 10.1097/ICO.0b013e31818d382d.
PMID:

 

19411971

 

[PubMed – indexed for MEDLINE]
Related citations
34.
Pathogenetic mechanisms and treatment options for ophthalmic pterygium: trends and perspectives (Review).
Detorakis ET, Spandidos DA.
Int J Mol Med. 2009 Apr;23(4):439-47. Review.
PMID:

 

19288018

 

[PubMed – indexed for MEDLINE]
Related citations
35.
Vascular endothelial growth factor gene 460 polymorphism is associated with pterygium formation in female patients.
Tsai YY, Chiang CC, Bau DT, Cheng YW, Lee H, Tseng SH, Tsai FJ.
Cornea. 2008 May;27(4):476-9. doi: 10.1097/ICO.0b013e3181644581.
PMID:

 

18434853

 

[PubMed – indexed for MEDLINE]
Related citations
36.
Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A.
Curr Eye Res. 2008 Jan;33(1):23-8. doi: 10.1080/02713680701799101.
PMID:

 

18214740

 

[PubMed – indexed for MEDLINE]
Related citations
37.
Evaluation of transforming growth factor and vascular endothelial growth factor polymorphisms in Taiwan Chinese patients with pterygium.
Bau DT, Chiang CC, Tsai YY, Lee CC, Tsai Y, Lin CC, Tsai CH, Tsai FJ.
Eur J Ophthalmol. 2008 Jan-Feb;18(1):21-6.
PMID:

 

18203080

 

[PubMed – indexed for MEDLINE]
Related citations
38.
[Preliminary study of vascular mimicry in pterygium].
Li YP, Zhu Z, Zhang WX.
Zhonghua Yan Ke Za Zhi. 2007 Oct;43(10):872-5. Chinese.
PMID:

 

18201521

 

[PubMed – indexed for MEDLINE]
Related citations
39.
[Blood vessel multiply and significance of expression of Cox-2, VEGF in pterygium].
Yan M, Li Z, Liu G, Peng C, Zhou Y, Wang F.
Yan Ke Xue Bao. 2007 Mar;23(1):20-4. Chinese.
PMID:

 

17444036

 

[PubMed – indexed for MEDLINE]
Related citations
40.
Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia.
Hosseini H, Nejabat M, Khalili MR.
Med Hypotheses. 2007;69(4):925-7. Epub 2007 Mar 26.
PMID:

 

17367957

 

[PubMed – indexed for MEDLINE]
Related citations
41.
Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1.
Aspiotis M, Tsanou E, Gorezis S, Ioachim E, Skyrlas A, Stefaniotou M, Malamou-Mitsi V.
Eye (Lond). 2007 Aug;21(8):1095-101. Epub 2006 Jun 23.
PMID:

 

16823458

 

[PubMed – indexed for MEDLINE]
Related citations
42.
Endothelial progenitor cells in pterygium pathogenesis.
Lee JK, Song YS, Ha HS, Park JH, Kim MK, Park AJ, Kim JC.
Eye (Lond). 2007 Sep;21(9):1186-93. Epub 2006 May 26.
PMID:

 

16732212

 

[PubMed – indexed for MEDLINE]
Related citations
43.
UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling.
Di Girolamo N, Wakefield D, Coroneo MT.
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2430-7.
PMID:

 

16723453

 

[PubMed – indexed for MEDLINE] 

Free Article

Related citations
44.
Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia.
Gebhardt M, Mentlein R, Schaudig U, Pufe T, Recker K, Nölle B, Al-Samir K, Geerling G, Paulsen FP.
Ophthalmology. 2005 Jun;112(6):1023-30.
PMID:

 

15885787

 

[PubMed – indexed for MEDLINE]
Related citations
45.
Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia.
Jin J, Guan M, Sima J, Gao G, Zhang M, Liu Z, Fant J, Ma JX.
Cornea. 2003 Jul;22(5):473-7.
PMID:

 

12827055

 

[PubMed – indexed for MEDLINE]
Related citations
46.
Connective tissue growth factor in pterygium: simultaneous presence with vascular endothelial growth factor – possible contributing factor to conjunctival scarring.
van Setten G, Aspiotis M, Blalock TD, Grotendorst G, Schultz G.
Graefes Arch Clin Exp Ophthalmol. 2003 Feb;241(2):135-9. Epub 2002 Dec 24.
PMID:

 

12605268

 

[PubMed – indexed for MEDLINE]
Related citations
47.
Angiogenesis in pterygium: morphometric and immunohistochemical study.
Marcovich AL, Morad Y, Sandbank J, Huszar M, Rosner M, Pollack A, Herbert M, Bar-Dayan Y.
Curr Eye Res. 2002 Jul;25(1):17-22.
PMID:

 

12518239

 

[PubMed – indexed for MEDLINE]
Related citations
48.
Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia.
Lee DH, Cho HJ, Kim JT, Choi JS, Joo CK.
Cornea. 2001 Oct;20(7):738-42.
Shopping Cart